冠心病杂志

Atrial fibrillation is an irregular and often rapid heart rate that can increase your risk of strokes, heart failure and other heart-related complications. Symptoms often include heart palpitations, shortness of breath and weakness. Blood clots forming in the heart may circulate to other organs and lead to blocked blood flow (ischemia) Treatment may include medications and other interventions to try to alter the heart's electrical system. The heart's two upper chambers (the atria) beat chaotically and irregularly.

COVID-19's cardiac problems have the potential to be fatal. Myocardial damage is a multifactorial event in the setting of COVID-19 that has piqued researchers' curiosity. A systematic review of the literature was conducted, followed by a meta-analysis. The databases MEDLINE and EMBASE were combed. The publications were reviewed by two independent reviewers for the outcome of myocardial damage.

Cardiovascular mortality, sudden cardiac death, and heart failure are all linked to complete left bundle branch block (cLBBB). The appearance of cLBBB on an electrocardiogram (ECG) elevates clinical awareness and frequently necessitates additional cardiac investigations and clinical follow-up. Incomplete LBBB (iLBBB) is characterised by a QRS shape similar to cLBBB but with a QRS duration (QRSD) of less than 120 milliseconds. Patients with iLBBB have a poor clinical profile and a long natural history, hence their clinical profile and natural history are mostly unknown. The purpose of this study is to evaluate the clinical profile of iLBBB patients, the rate and risk factors for progression to cLBBB, and the outcome of iLBBB patients.

Although not all healthcare practitioners are on board with digital health, it is becoming more prevalent in the clinical setting. By providing creative methods to combine technology, connection, and people, modern technologies and digital appliances have a major influence on the way we care for patients. In the follow-up of these patients, remote monitoring and follow-up have shown to be superior to traditional treatment, and they have become the new standard of care. It focuses on patient empowerment and has yielded encouraging outcomes, but it also emphasises the need to improve the system's automaticity in order to achieve appropriate follow-up adherence rates. Patients who have cardiac implanted electronic devices must have device follow-up as part of their therapy (CIEDs). PPMs, ICDs,

Tuberculosis and Cardiovascular Disease (CVD) have a huge global impact. Tuberculosis and cardiovascular disease can not only occur at the same time, but they can also impact one another's risk. A direct effect of Mycobacterium TB on the heart and coronary arteries enhanced immune activation and cytokine production, and cross-reactivity of anti-mycobacterial antibodies against cardiovascular tissue are all possible contributions to CVD risk in tuberculosis. Several pathogens have been associated with increased cardiovascular disease (CVD) risk. Whether this occurs with Mycobacterium tuberculosis infection is unclear. Tuberculosis was linked to a higher incidence of AMI (adjusted Hazard Ratio (HR) of 198, 95 percent confidence intervals (CI) of 13-30). When the study was limited to pulmonary TB, the results were comparable Tuberculosis has been linked to a higher incidence of AMI.